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OBJECTIVES: Human papillomavirus (HPV) in oral car-
cinoma (OSCC) and potentially malignant disorders
(OPMD) is controversial. The primary aim was to calcu-
late pooled risk estimates for the association of HPV with
OSCC and OPMD when compared with healthy oral
mucosa as controls. We also examined the effects of
sampling techniques on HPV detection rates.
METHODS: Systematic review was performed using
PubMed (January 1966–September 2010) and EMBASE
(January 1990–September 2010). Eligible studies included
randomized controlled, cohort and cross-sectional stud-
ies. Pooled data were analysed by calculating odds ratios,
using a random effects model. Risk of bias was based on
characteristics of study group, appropriateness of the
control group and prospective design.
RESULTS: Of the 1121 publications identified, 39 cross-
sectional studies met the inclusion criteria. Collectively,
1885 cases and 2248 controls of OSCC and 956 cases and
675 controls of OPMD were available for analysis. Sig-
nificant association was found between pooled HPV-DNA
detection and OSCC (OR = 3.98; 95% CI: 2.62–6.02) and
even for HPV16 only (OR = 3.86; 95% CI: 2.16–6.86). HPV
was also associated with OPMD (OR = 3.87; 95% CI: 2.87–
5.21). In a subgroup analysis of OPMD, HPV was also
associated with oral leukoplakia (OR = 4.03; 95% CI: 2.34–
6.92), oral lichen planus (OR = 5.12; 95% CI: 2.40–10.93),
and epithelial dysplasia (OR = 5.10; 95% CI: 2.03–12.80).
CONCLUSIONS: The results suggest a potentially
important causal association between HPV and OSCC
and OPMD.
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Introduction
The speciﬁc role of human papillomaviruses (HPV) in
the development of premalignant and oral squamous cell
carcinoma (OSCC) continues to be debated topic (Syr-
ja¨nen and Syrja¨nen, 2000, Adelstein et al, 2009) despite
the well-established fact that the vast majority of cervical
squamous cell carcinoma of uteri (CC) is attributable to
HPV infection (zur Hausen, 1994, 2002, zur Hausen and
de Villiers, 1994). The papillomavirus family (Papillo-
maviridae) is a highly diverse group of small non-
enveloped DNA tumor viruses (de Villiers et al, 2004).
HPVs are identiﬁed by complete sequence analysis, and
classiﬁed by type, on the basis of their sequence
homology within the capsid protein gene L1, the most
conserved gene within the genome (de Villiers et al, 2004;
de Villiers and Gunst, 2009). Hence, HPV types are
referred to as genotypes. In humans, over 120 HPV
genotypes have been fully sequenced (de Villiers et al,
2004; de Villiers and Gunst, 2009). HPVs have also been
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classiﬁed as high or low risk types based on the clinical
behavior of the virally infected tissues.
The HPV virion is approximately 55 nm in diameter
and consists of a closed circular double stranded DNA
genome, with a size of size almost 8000 bp. Overall, the
HPV genome has the capacity to encode eight proteins:
E1, E2, E4-E7, the non-structural proteins involved
mainly in replication, transcription and transformation
and L1 and L2, the structural proteins that compose
the capsid. HPVs speciﬁcally target the undiﬀerentiated
proliferative basal cells of epithelial mucosa that are
exposed following tissue trauma. HPV proteins, espe-
cially the oncoproteins E6 and E7 of the high risk
HPVs (HR-HPVs), interact with diﬀerent degrees of
aﬃnity, with host cell proteins to disturb the normal
epithelial diﬀerentiation and apoptosis by stimulating
cellular proliferation, DNA synthesis and inhibition of
cell cycle regulators (Doorbar, 2007). The interactions
between E7 and pRB and E6 and p53 have been
characterized (Mu¨nger et al, 1989; Werness et al, 1990).
Continued and aberrant expression of the E6 and E7
genes of the HR-HPVs leads to genomic instability, and
mutational events that can result in malignant trans-
formation (Stanley et al, 2007). Proteins of low-risk
HPVs (LR-HPVs) have a low aﬃnity for tumor
suppressor proteins. Thus, these viruses have low
oncogenic potential and the infections are usually self-
limited. Persistent infection with HR-HPVs increases
the risk of cancer, while the low-risk types may be
associated with benign lesions. In women with CC, to
date 15 HR-HPV types (HPV 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82), three probable (HPV
26, 53, and 66) and 12 LR-HPV types (HPV 6, 11, 40,
42, 43, 44, 54, 61, 70, 72, 81, and 89) have been
identiﬁed, based on pooled case–control data. HPV16 is
the most potent type to cause cancer at diﬀerent
anatomical sites, causing around 50% of all cervical
cancer (Mun˜oz et al, 2004, IARC, 2007; Smith et al,
2007).
In normal oral mucosa, the following HPV types have
been detected: HPV 2, 6, 7, 11, 13, 16, 18, 31, 33, and 35.
The signiﬁcance of HPV in healthy-appearing oral
mucosa is not known. To date, in oral benign and
malignant lesions so far, 24 types have been detected:
HPV 1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 31, 32, 33, 35, 39,
45, 51, 52, 55, 56, 57, 58, 59, 66, 69, 72, and 73 (Syrja¨nen
and Syrja¨nen, 2000, Kreimer et al, 2010). Of signiﬁcance
these included 13 HR-HPVs and probable HR-HPV
that have been associated with CC.
As early as 1983, an original observation and
hypothesis was presented, that implicated HPV as a
risk factor in a subset of oral cancers (Syrjanen et al,
1983). Since then, several studies have focused on
HPV detection in oral cancer but results have been
conﬂicting (Miller and White, 1996, Syrja¨nen and
Syrja¨nen, 2000, Ragin et al, 2007, Adelstein et al,
2009) and lacked the design rigor of case–controls
studies. By contrast, the data on HPV association with
oro-pharyngeal cancer is increasingly compelling (Mel-
lin et al, 2000, D’Souza et al, 2007; Adelstein et al,
2009; Ang et al, 2010). Miller and Johnstone were the
ﬁrst to present a meta-analysis based on pooled data
from non-controlled studies between 1982 and 1997 to
estimate HPV prevalence in tissues with precancerous
and cancerous features and normal oral mucosa. They
found that the frequency of HPV detection in normal
oral mucosa [10.0%; 95% conﬁdence interval (CI),
6.1–14.6%] was signiﬁcantly less than in leukoplakia
(22.2%; 95% CI, 15.7–29.9%), intra-epithelial neopla-
sia (26.2%; 95% CI, 19.6–33.6%), verrucous carci-
noma (29.5%; 95% CI, 23–36.8%), and OSCC
(46.5%; 95% CI, 37.6–55.5%). The pooled odds ratio
(OR) for the subset of studies directly comparing the
prevalence of HPV in normal mucosa and OSCC was
5.4, conﬁrming the trend observed in the overall
sample (Miller and Johnstone, 2001), but once again
their analyses were not based on case–control studies.
In the review of Kreimer et al (2005), HPV prevalence
in OSCC was 23.5% (Kreimer et al, 2005). HPV16 was
the most common type present and was detected in
16.0% of OSCC, accounting for almost 70% of HPV-
positive cases. HPV18 was the next most common
oncogenic HPV type, detected in 8% of OSCC (Kreimer
et al, 2005; Adelstein et al, 2009).
The wide variations in HPV detection rates have been
explained by diﬀerences in sampling (e.g. oral scrapings,
cells acquired with mouthwash, or biopsies) and the
sensitivity and speciﬁcity of HPV testing methods.
Kellokoski et al (1992) showed that the same samples
taken from healthy oral mucosa tested HPV-positive in
3.8% and 29.4% with dot blot hybridization and
polymerase chain reaction (PCR), respectively.
Oral potentially malignant disorders
The common term oral potentially malignant disorders’
(OPMD) has been suggested for oral precancers,
including both oral precancerous lesions (e.g. leukopla-
kia, erythroplakia, and oral proliferative verrucous
leukoplakia) and oral precancerous conditions (e.g.
lichen planus and submucous ﬁbrosis). All oral mucosal
lesions that carry a risk of malignant transformation are
included under this term (Warnakulasuriya et al, 2007;
van der Waal, 2009). In the present systematic review,
the following OPMD were included: oral lichen planus
(OLP), leukoplakia, erythroplakia and oral proliferative
verrucous leukoplakia (OPVL).
Oral lichen planus is a chronic autoimmune disorder
of unknown etiology in which predominantly T lym-
phocytes accumulate beneath the epithelium and
increase the rate of diﬀerentiation of stratiﬁed squa-
mous epithelium, resulting in either epithelial thickening
or atrophy with or without ulceration (Epstein et al,
2003). In the literature published prior to 1998, 107
OLP samples were tested for the presence of HPV DNA
with either in situ hybridization (ISH) or dot blot
hybridization and 23% were positive. The most
prevalent types detected were HPV 6 and 11, followed
by HPV 16. Since that time, 1929 samples (either
scrapings or biopsies) from normal oral mucosa, have
been tested for HPV DNA, and 11% were positive
(Syrja¨nen and Syrja¨nen, 2000). In comparison with
normal oral mucosa the HPV detection rate in OLP was
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twice as high. Although additional studies (Giovannelli
et al, 2002; Campisi et al, 2004a,b) have detected the
presence of HPV in OLP, there has been no systematic
review of the literature evaluating the strength of this
association.
Leukoplakia has been deﬁned as white plaques of
questionable risk having excluded (other) known dis-
eases or disorders that carry no increased risk for cancer
(Warnakulasuriya et al, 2007). In a review evaluating
the literature prior to 1998, 890 leukoplakic and
keratotic lesions had been tested for HPV DNA, of
which 25.4% were HPV-positive (Syrja¨nen and Syrja¨-
nen, 2000). Recently, Szarka et al (2009) detected HPV
more frequently in lesions than in controls (P £ 0.001 in
all comparisons). HPV prevalence increased gradually
with increasing severity of the lesions; 32.8%, 40.9%,
and 47.7% in OLP, oral leukoplakia (OL), and OSCC,
respectively. HPV copy number distribution patterns
roughly corresponded to prevalence rates, but OLP and
OL were comparable. HPV prevalence diﬀered signiﬁ-
cantly between two OLP groups classiﬁed as either
higher malignancy risk or lower malignancy risk lesions
(42.6 vs 22.4%).
Erythroplakia has long been considered as the oral
lesion with the highest potential for malignant transfor-
mation. The 1978 WHO deﬁnition is still used, and
describes erythroplakia is a ﬁery red patch that cannot
be characterized clinically or pathologically as any other
deﬁnable disease’ (Warnakulasuriya et al, 2007). By
1998, only 11 oral erythroplakia lesions had been tested
for HPV DNA, and 54.5% tested HPV16 positive
(Syrja¨nen and Syrja¨nen, 2000).
Oral proliferative verrucous leukoplakia is a rare, but
distinct high-risk clinical form of OL (van der Waal,
Reichart, 2008, Mete et al. 2010). Conﬂicting results
exist in the literature concerning the presence of HPV in
OPVL (Palefsky et al, 1995; Campisi et al, 2004a,b;
Bagan et al, 2007) . By 1998, 215 OPVL lesions had been
tested for HPV, with the detection rate of 26.5%
(Syrja¨nen and Syrja¨nen, 2000).
There are few follow-up studies on HPV and OPMD.
In 1996, Nielsen et al found that an overall HPV
detection rate in premalignant lesions was 40.8%
(n = 49), while no patients in the control group
(n = 20) were HPV-positive. All patients who devel-
oped oral cancers within 4–12 years were positive for
HPV. By contrast, Yang et al (2009) detected HPV
DNA in 22.8% of 167 OL lesions, which underwent
malignant transformation. The most signiﬁcant predic-
tor for malignant transformation was found to be the
recurrence of OL after treatment (P = 0.03), and not
the HPV status.
The primary aim of this systematic review was to
calculate the pooled estimates of the odds ratio (OR) for
the association of HPV with OSCC and OPMD (cases),
when compared with healthy oral mucosa (controls). We
tested the null hypothesis that there is no diﬀerence in
HPV prevalence between cases and controls. The
secondary aim was to examine the eﬀect of sampling
technique (tissue vs exfoliated cells) on these risk
estimates of HPV infection.
Materials and methods
Literature search
A systematic literature search of MEDLINE from 1966
through September 2010 and EMBASE from 1990
through September 2010 was conducted without lan-
guage restriction entering the following terms: HPV,
human papillomavirus, oral squamous cell carcinoma,
oral precancer, oral premalignancy, oral cancer, oral
verrucous carcinoma, lichenoid, oral lichen planus, oral
dysplasia, leukoplakia, erythroplakia, submucous ﬁbro-
sis, oral verrucous leukoplakia, oral keratoacanthoma,
oral Bowen’s disease, oral, mouth, oropharyngeal, risk
factor, frequency, prevalence, epidemiology and serol-
ogy as both medical subject heading (MeSH) terms and
text words. Moreover, reference lists of previous meta-
analyses and other relevant papers were searched. All
abstracts were reviewed independently by two preselect-
ed standardized reviewers (AA, GL or PA, IB). When
the article was considered relevant by the two reviewers,
the full papers were obtained and evaluated.
Inclusion criteria
Studies addressing the relationship between HPV infec-
tion and OSCC and between HPV infection and OPMD
were included in the present systematic review when they
met the following criteria:
• Randomized controlled trials (RCTs) testing HPV
vaccine efﬁcacy and including OSCC and ⁄ or OPMD
among outcomes or;
• Cohort studies comparing OSCC and ⁄ or OPMD
incidence among subjects with and without HPV
infection or;
• Case–control or cross-sectional studies comparing
HPV infection among subjects with and without
OSCC and ⁄ or OPMD.
Furthermore, the following criteria had to be met:
• Clinical and histological diagnosis of OSCC and
OPMD speciﬁed;
• HPV infection based on detection of HPV by DNA
detection in the tissue biopsies or exfoliated cytology
samples;
• Studies that have healthy individuals as controls.
Studies were excluded if they:
• Included patients with malignancies different from
cancer of the mouth (C01-C06, excluding the C01.9,
base of the tongue), e.g. oro-pharyngeal cancer, and
when it was impossible to extract cancer of the
mouth data;
• Included among cases or controls, HIV-positive
subjects, transplant patients or deﬁned immunosup-
pression;
• Investigated pediatric patients (under 17 years) spe-
ciﬁcally.
Critical appraisal
From all eligible reports that met the inclusion criteria,
two reviewers (AA and PA) independently extracted
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relevant information and HPV DNA data. The follow-
ing quality criteria were adopted:
1. For RCTs, allocation concealment method, masking
of the study and loss of participants to follow up;
2. For cohort studies, appropriateness of the control
group: subjects belonging to the control group must
not diﬀer signiﬁcantly from those of the study group,
except for HPV infection (gender and age must be
matched, subjects of the control group must be
selected from the study base), length of follow up (at
least 5 years) and prospective design (i.e. data and
samples collected speciﬁcally for the study).
3. For case–control studies, characteristics of the study
group (consecutive, unselected patients with OSCC
and ⁄ or OPMD), appropriateness of the control
group: subjects belonging to the control group must
not diﬀer signiﬁcantly from those of the study group,
except for the diagnosis of OSCC and ⁄ or OPMD
(gender and age must be matched, subjects of the
control group must be selected from the study base)
and prospective design (i.e. data and samples col-
lected speciﬁcally for the study).
Each of the criteria for RCTs, cohort studies and
case–control studies were rated as met’, unmet’, or
unclear’. The global validity of the study was assessed
using three categories:
1. Low risk of bias: all of the criteria met;
2. Moderate risk of bias: one or two criteria unclear;
3. High risk of bias: at least one criterion unmet or three
criteria unclear.
Data extraction
A standardized data extraction form was prepared and
tested for review of three articles independently by ﬁve
reviewers, which resulted in some changes in the form.
Critical appraisal of all the studies that had been selected
based on the inclusion criteria was then carried out
without masking the name of authors, institutions or
journal. The form was used to extract data from the
study. The eligibility, validity and design including: HPV
DNA detection methods, tissue samples for HPV DNA
testing within or immediately adjacent to the actual
lesion, intra-individual controls from mucosa not adja-
cent to the lesion (site speciﬁed) or inter-individual
controls (site speciﬁed), and outcome information
(including HPV type) were recorded on the extraction
form for each study. When studies included data from
diﬀerent anatomical sites, only data on the cancers of the
mouth were extracted. When this was not possible, the
study was excluded. Furthermore, detailed information
was sought on the methodology of HPV DNA detection
from the eligible papers. This included how the samples
were collected (rinse, brush, biopsy that provide either
exfoliated cells or tissue for HPV-testing), and the type of
HPV detection method (ISH, PCR, other DNA tech-
niques), HPV genotyping and HPV quantiﬁcation with
real-time PCR on DNA or mRNA level. Positive and
negative controls were always included in theHPV testing
methods, but not speciﬁcally extracted onto the form.
Statistical analysis
The data were analyzed using Review Manager 5, a
copyrighted freeware developed by the Cochrane Col-
laboration, for preparing and maintaining reviews
(www.cochrane-net.org/revman). The primary analysis
was the prevalence of HPV DNA in lesions and in the
samples taken from the controls at any anatomical site
of the mouth. The association between oral lesions and
HPV prevalence was estimated by calculating OR and
the 95% conﬁdence interval (CI). When absence of
events in one of the groups caused problems with
computation of OR, 0.5 was added to all values for that
study, except when absence of events involved both
study and control groups, in this case OR was undeﬁned
(Yu et al, 2010). As heterogeneity among studies was
expected on the basis of large variability in HPV
prevalence across diﬀerent countries, a random eﬀect
was used to calculate the summary estimate using
Mantel-Haenszel method (Mantel, 1958, Greenland
and Robins, 1985) .
A sensitivity analysis was planned, excluding studies
of lower methodological quality (i.e. studies at high risk
of bias). To investigate potential for publication bias,
the funnel plot of the OR of the included studies was
checked for asymmetry (Sterne and Egger, 2001).
Statistical heterogeneity was assessed with the I2 statistic
that has been conventionally adopted to indicate low,
moderate, and high heterogeneity to values of 25%,
50%, and 75% (Higgins et al, 2003).
Results
Results of the search strategy
In total, 1121 papers were identiﬁed from the database
searches and the full texts of 62 papers were acquired
for further inspection. Of these, 24 papers were
excluded because of inappropriate study design, while
39 studies met the criteria of a case–control design.
Among these papers, no RCTs or cohort studies were
identiﬁed. The papers included in this analysis were
published between 1987 and 2009, included the
following languages: English, Chinese, German, and
Spanish.
Critical appraisal of the included studies on OPMD and
OSCC
On the basis of the established criteria, the risk of bias in
the studies included was quite high. In fact, none of the
39 included studies met all three criteria, three studies
met two criteria (Giovannelli et al, 2002; Herrero et al,
2003; Debanth et al, 2009), 11 met one criterion (Lei
et al, 1996; Mao et al, 1996; Nielsen et al, 1996; Bustos
et al, 1999; Patiman et al, 2001; Kansky et al, 2003;
Koppikar et al, 2005; Hansson et al, 2005; Cianfriglia
et al, 2006; Anaya-Saavedra et al, 2008), while the
remainder of the studies did not fulﬁll any of the
predeﬁned quality criteria. In particular, only four
studies enrolled consecutive patients. In nine studies,
cases and controls were matched and four studies had a
prospective design. No study was deﬁned low risk of
bias and only two were evaluated as a moderate risk of
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bias (Herrero et al, 2003; Debanth et al, 2009). For this
reason, sensitivity analysis was not performed.
HPV and OSCC
The characteristics of the studies included in this review
are summarized in Table 1 and the results of the meta-
analysis are shown in Figure 1. The 33 studies com-
prised a total of 1885 OSCC patients and 2248 controls.
HPV prevalence across all studies was higher among
OSCC samples than in controls with the exception of
four investigations (Cox et al, 1993; Herrero et al, 2003;
Sugiyama et al, 2003; Tachezy et al, 2009). The risk
estimates for HPV association with OSCC varied from
0.32 (95% CI: 0.02–5.70) to 363.00 (95% CI: 13.76–
9575.31), with signiﬁcant heterogeneity between the
studies (I2 = 71%). The pooled OR across all studies
was 3.98 (95% CI: 2.62–6.02), indicating a signiﬁcantly
increased risk of HPV among the cases, when compared
with the controls.
Figure 1 also shows the secondary analysis of HPV
prevalence in cases and controls, stratiﬁed by the
HPV sampling technique. In studies using biopsies for
HPV detection in both cases and controls, the risk for
HPV association had an OR = 3.30; 95%CI: 2.08–5.23.
In studies that used biopsies for HPV testing of the
OSCC cases and exfoliate cells for the controls the risk
for HPV association had an OR = 8.61; 95% CI: 3.52–
21.09. In studies using exfoliated cells for HPV testing of
both OSCC cases and controls, the risk estimates were
not statistically signiﬁcant. Sub-analysis also disclosed
that the heterogeneity was mainly attributed to the two
small subgroups, while studies examining tissue only
showed an acceptable level of heterogeneity (I2 = 47%).
The visual examination of the symmetry of the funnel
plot (Figure 2) did not suggest a large publication bias.
Figure 3 shows the comparison between the presence
of HPV16 among OSCC and controls. A total of 725
OSCC cases were compared with 539 controls in 18
included studies. An OR of 3.86 (95% CI: 2.16–6.87)
was statistically signiﬁcant. Heterogeneity was less than
that detected in the OPMD analysis (I2 = 49%).
HPV and OPMD
The characteristics of the studies included in the review
are summarized in Table 2 and the results of the meta-
analysis are shown in Figure 4. Altogether, there were
Table 1 Characteristics of studies investigat-
ing human papillomavirus infection in oral
squamous cell carcinoma and control samples
Study
Sample
Detection method aCases Controls
Maitland et al, 1987 Tissue Tissue ISH
Chang et al, 1989 Tissue Tissue ISH
Yeudall and Campo, 1991 Tissue Tissue PCR
Cox et al, 1993 Tissue Tissue ISH
Holladay and Gerald, 1993 Tissue Tissue PCR
Mao, 1995 Exfoliated cells Exfoliated cells PCR
Lei et al, 1996 Tissue Tissue PCR
Mao et al, 1996 Tissue Tissue PCR
Cruz et al, 1996 Tissue Tissue PCR
Gopalakrishnan et al, 1997 Tissue Tissue PCR
Wang et al, 1998 Tissue Tissue PCR
Bustos et al, 1999 Tissue Exfoliated cells ISH
Sand et al, 2000 Tissue Tissue PCR
Bouda et al, 2000 Tissue Exfoliated cells PCR
Cao et al, 2000 Tissue Tissue PCR
Patiman 2001 Tissue Tissue PCR
Patiman et al, 2001 Tissue Tissue PCR
Giovannelli et al, 2002 Exfoliated cells Exfoliated cells PCR
Herrero 2003 Exfoliated cells Exfoliated cells PCR
Regezi et al, 2002 Tissue Tissue PCR
Sugiyama et al, 2003 Tissue Tissue PCR
Kansky et al, 2003 Tissue Tissue PCR
Chang et al, 2003 Tissue Tissue PCR
Zhang et al, 2004 Tissue Tissue PCR
Koppikar et al, 2005 Tissue Exfoliated cells PCR
Hansson et al, 2005 Exfoliated cells Exfoliated cells PCR
Luo et al, 2007 Exfoliated cells Exfoliated cells PCR
da Silva et al, 2007 Tissue Tissue PCR
Anaya-Saavedra et al, 2008 Tissue and exfoliated cells Exfoliated cells PCR
Llamas-Martı´nez et al, 2008 Tissue Tissue PCR
Majunder et al, 2009 Tissue and exfoliated cells Exfoliated cells PCR
Tachezy et al, 2009 Exfoliated cells Exfoliated cells PCR
Szarka et al, 2009 Tissue Exfoliated cells PCR
ISH, in situ hybridization.
aAt this stage, no distinction was made according to the PCR methods, whether single PCR,
nested PCR or quantitative PCR. In most studies, single PCR was used with the primers targeting
L1 gene. Thus, also no distinction was made at this stage between the HPV genes ampliﬁed for
HPV testing nor the primers used for HPV testing were targeting the L1 or E genes.
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956 patients with OPMD and 675 controls in these
studies. In all of the investigations, the HPV detection
rate was higher in the OPMD group than in the
controls. The OR of HPV DNA detection in OPMD
varied from 1.67 (95% CI: 0.17–16.22) to 363.00 (95%
CI: 6.41–20565.48). The pooled estimate across all
studies was 3.87 (95% CI: 2.87–5.21), indicating a
signiﬁcantly increased risk of HPV among OPMD
patients when compared with controls. Interestingly,
despite the great variability in these studies, the heter-
ogeneity of the results of the whole group was close to 0
(I2 = 1%).
Figure 4 also shows the secondary analysis of HPV
prevalence in cases and controls stratiﬁed by the method
of sampling. Studies using either tissue biopsies or
exfoliated cells for HPV testing (both in cases and
Figure 1 Forest plot of human papillomavirus (HPV) prevalence in oral squamous cell carcinoma (OSCC) and control samples. Biopsied samples
and exfoliated cells were used for HPV testing both in cases and controls in 1.1.1 and 1.1.2, respectively. In 1.1.3 the biopsy samples of OSCC were
tested for HPV while in the controls exfoliated cells were used for HPV testing. Studies are ordered by year of publication. The square and
horizontal line correspond to the study odds ratio and the 95% conﬁdence intervals. The area of the squares reﬂects the weight each trial
contributes in the meta-analysis. The diamond represents the combined odds ratio with its 95% conﬁdence intervals
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controls) showed very similar risk estimates: OR = 3.69
(95% CI: 2.22–6.13) and OR = 4.66 (95% CI: 3.00–
7.23), respectively. However, when biopsies were used
for HPV testing in the OPMD cases and exfoliated cells
in the controls, the diﬀerence in HPV prevalence
between the cases and controls lost its signiﬁcance.
As shown in Figure 5, the visual examination of the
symmetry of the funnel plot did not suggest a large
publication bias.
In a subgroup analysis of diﬀerent entities of OPMD
(Figure 6), the risk estimates for their association with
HPV were statistically signiﬁcant as follows: (1) unspec-
iﬁed OMPD (OR 4.44; 95% CI: 2.64–7.49), (2) lichen
planus (OR 5.12; 95% CI: 2.40–10.93), (3) leukoplakia
(OR 4.03; 95% CI: 2.34–6.92), and (4) epithelial
dysplasia (OR 5.10; 95% CI: 2.03–12.80). In these
subgroups, we also calculated the pooled estimates for
HPV16 associations as summarized in Figure 7. Diﬀer-
ence between cases and controls remained statistically
signiﬁcant for OLP (OR 5.61; 95% CI: 2.42–12.99) and
OL (OR 4.47; 95% CI: 2.22–8.98).
Discussion
This study showed a strong association between the
presence of HPV DNA, and speciﬁcally HPV16, and
OSCC. This was not the case with OPVL and carcinoma
in situ (CIS) because of the small size of the cohorts.
This is the ﬁrst and most comprehensive meta-analysis
performed at this point in time that utilized a strict case–
Figure 2 Funnel plot of the studies investi-
gating human papillomavirus (HPV) infection
in oral squamous cell carcinoma (OSCC) and
control samples
Figure 3 Forest plot of human papillomavirus (HPV) 16 prevalence in oral squamous cell carcinoma (OSCC) and control samples
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control setting. For the present analysis, the literature
was reviewed up to September 2010.
In the emerging era of HPV vaccines, interest in the
role of HPV in cancers other than the genital tract has
substantially increased. Recently, the association of
HPV with a subset of oro-pharyngeal and particularly
tonsillar cancer has been conﬁrmed (Mellin et al, 2000;
D’Souza et al, 2007; Adelstein et al, 2009; Ang et al,
2010). The role HPV in oral cancer (OSCC) has been
under debate since the ﬁrst report suggested this
association in 1983 (Syrjanen et al, 1983). In this
systematic review, we investigated the prevalence of
HPV in OSCC and OPMD in strict case–control
settings. Importantly, we only included studies where
all lesions were histologically conﬁrmed. In addition,
unlike previous reviews, we included only studies
detecting HPV in tissue samples or exfoliated cells. As
a result of the adherence to these strict inclusion criteria,
only 39 studies out of 1121 reports were eligible for the
analysis. For OSCC, 33 studies including 1885 cancers
and 2248 controls were analyzed, giving this review a
substantial statistical power. Importantly, all studies
based exclusively on HPV serology were excluded,
because HPV seropositivity only signiﬁes a past- or
present-HPV exposure of the individual, with no indi-
cation of the exact site of infection. Most HPV serology
studies have correlated HPV seropositivity with genital
HPV infection and the concordance has been poor.
Furthermore, no studies exist that demonstrate HPV
seroconversion after oral HPV infection.
HPV and OSCC
Several previous reviews exist on HPV prevalence in
normal, benign, premalignant, and malignant oral
lesions. However, none of the earlier studies fulﬁll the
strict deﬁnitions set forth for the present analysis. Miller
and Johnstone were the ﬁrst to publish a meta-analysis
on HPV prevalence in precancer lesions, cancer and
normal oral mucosa. Pooled data from non-controlled
studies published between 1982 and 1997 showed that
HPV was 2–3 times more likely to be detected in oral
precancer lesions, and 4.7 times more likely to be present
in oral carcinomas, when compared with normal
mucosa (Miller and Johnstone, 2001). Pooled OR for
a subset of studies directly comparing the prevalence of
HPV in normal mucosa and OSCC was 5.37. The
probability of detecting HR-HPV in OSCC was 2.8
times higher than that of LR-HPV types. Syrja¨nen
reviewed the HPV literature published prior to 1998,
and the pooled HPV detection rates in normal oral
mucosa, OL and OSCC were 13% (with PCR), 25%
(PCR or ISH) and 33% (PCR), respectively (Syrja¨nen
and Syrja¨nen, 2000).
The present meta-analysis showed that HPV signiﬁ-
cantly increases the risk for OSCC, as compared with
the controls (OR 3.98, 95% CI: 2.62–6.02). The pooled
HPV prevalence was 33.7% in the OSCC group and
12.0% in controls, which closely agrees with the ﬁndings
by Termine et al (2008). However, the present ﬁndings
are somewhat lower than those detected by Miller and
Johnstone (2001) but higher than reported by Kreimer
et al (2005) and Smith et al (2004). Kreimer et al (2010)
found any HPV in 4.5% (95% CI: 3.9–5.1) of the oral
exfoliate samples from 4070 healthy individuals while
HPV16 genotype accounted for 28% of all HPV types
detected.
Based on our results, we can also estimate that the
increased risk for OSCC is related mostly to HPV16
(pooled OR = 3.86; 95% CI: 2.16–6.87). However, the
studies included in our analysis showed moderate
heterogeneity. By contrast, Hobbs et al (2006) reported
only a weak association between HPV16 and OSCC
Table 2 Characteristics of studies investigating human papillomavirus infection in oral potentially malignant disorder (OPMD) and controls
Study Condition
Sample
Detection methodCases Controls
Maitland et al, 1987 Not otherwise speciﬁed OPMD Tissue Tissue PCR
Holladay and Gerald, 1993 Dysplasia; carcinoma in situ Tissue Tissue PCR
Cox et al, 1993 Lichen planus; leukoplakia Tissue Tissue PCR
Nielsen et al, 1996 Not otherwise speciﬁed OPMD Tissue Tissue PCR and ISH
Mao et al, 1996 Dysplasia; carcinoma in situ Tissue Tissue PCR
Gopalakrishnan et al, 1997 Proliferative verrucous leukoplakia Tissue Tissue PCR
Bouda et al, 2000 Oral hyperplasia; dysplasia Tissue Exfoliated cells PCR and ISH
Sand et al, 2000 Lichen planus; leukoplakia Tissue Tissue PCR
Patiman et al, 2001 Oral hyperplasia; dysplasia Tissue Tissue PCR
Giovannelli et al, 2002 Not otherwise speciﬁed OPMD Exfoliated cells Exfoliated cells PCR
Sugiyama et al, 2003 Dysplasia Tissue Tissue PCR
OFlatharta et al, 2003 Lichen planus Tissue Tissue PCR
Campisi et al, 2004a,b Lichen planus; leukoplakia Exfoliated cells Exfoliated cells PCR
Cianfriglia et al, 2006 Lichen planus; leukoplakia Exfoliated cells Exfoliated cells ISH
Luo et al, 2007 Not otherwise speciﬁed OPMD Exfoliated cells Exfoliated cells PCR
Llamas-Martı´nez et al, 2008 Leukoplakia Tissue Tissue PCR
Debanth 2009 OPMD; dysplasia Cells Cells RNA probe
Majunder et al, 2009 Leukoplakia Tissue Exfoliated cells PCR
Szarka et al, 2009 Lichen planus; leukoplakia Exfoliated cells Exfoliated cells PCR
ISH, in situ hybridization; OPMD, oral potentially malignant disorder.
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(OR = 2.0; 95% CI: 1.2–3.4). Importantly, the associ-
ation of HPV with OSCC was signiﬁcant only when
HPV was detected in the biopsy samples, being strongest
and most consistent when studies used biopsy samples
for HPV detection in both cases and controls. However,
the HPV association was also signiﬁcant when biopsy
samples of OSCC were compared with cytology of the
controls. This is consistent with the view that HPV
infection is multi-focal, i.e., exfoliated cytology is
positive even if taken outside of the lesion of interest.
This ﬁnding has also been conﬁrmed in the genital tract
(Barzon et al, 2010). The signiﬁcant association was
completely lost when only exfoliated cells were used to
analyse HPV in both the cases and the controls. This
ﬁnding is supported by Herrero et al (2003) who showed
that HPV DNA in exfoliated cells was not associated
with HPV DNA detection in OSCC biopsies. Thus,
when future studies exploring the relationship between
HPV and OSCC are designed, only biopsied tissues
should be used for HPV testing, to obtain the most
accurate results.
HPV and OPMD
To the best of our knowledge, this is the ﬁrst systematic
review showing a strong association between HPV
detection and OPMD, when the same sampling tech-
nique was used for both cases and controls (HPV DNA
detected in biopsy samples: OR = 3.69; 95% CI: 2.22–
6.13; HPV detected in exfoliated cells OR = 4.66; 95%
CI: 3.00–7.23). This signiﬁcance was lost, however, when
the sampling methods were diﬀerent for the cases and
the controls. Importantly, when the diﬀerent subgroups
of histological entities among OPMD were dissected, the
association of HPV with OLP, OL and epithelial
dysplasia remained statistically signiﬁcant, while OPVL,
and CIS did not reach statistical signiﬁcance. This might
be related to the limited number of cases and controls in
the OPVL-, epithelial dysplasia-, and CIS studies. HPV
prevalence in these OPMD lesions was quite similar as
reported by Miller and Johnstone (2001) and Syrja¨nen
and Syrja¨nen (2000), but higher in the controls than
reported by Kreimer et al (2010). However, Kreimer
et al, 2010 included in their meta-analysis only the
Figure 4 Forest plot of human papillomavirus (HPV) prevalence in oral potentially malignant disorder (OPMD) compared with control samples in
the 18 studies included. Biopsied samples and exfoliated cells were used for HPV testing both in cases and controls in 1.3.1 and 1.3.2, respectively.
In 1.3.3 the biosy samples of OSCC were tested for HPV while in controls exfoliated cells were used.
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studies with more than 50 subjects sampled with
scrapings or oral rinse only and tested with PCR.
The present meta-analysis also showed that HPV16
was signiﬁcantly increased in OL and OLP compared
with controls. The strength of the association between
HPV and OLP was somewhat unexpected and especially
interesting in view of the acceptance of OLP as a
premalignant condition. However, it is not easy to
explain why a chronically inﬂamed epithelium thought
to be attacked by T cells should be prone to support
HPV infection. One explanation could be that ulceration
is frequent in OLP making it more susceptibility for
HPV infection. Another potential reason could be the
chronic use of steroids which may induce immune
suppression that could regulate HPV replication. Fol-
low-up studies are needed to elucidate if the natural
histories of HPV-infected OL and OLP lesions diﬀer
from those without HPV infection. Until now, few
follow-up studies exist on the progression of OPMD
toward malignancy and the role of HPV remains
contradictory (Nielsen et al, 1996, Yang et al, 2009).
HPV testing
Human papillomavirus testing method is critical for the
estimation of HPV prevalence in diﬀerent oral diseases.
Sampling techniques together with widely divergent
PCR methods in diﬀerent studies explain most of the
variability in HPV prevalence among OSCC and control
samples. Most meta-analyses on HPV and genital
diseases are based on PCR as the gold standard.
General or consensus primers targeting L1 gene are
most frequently used for HPV detection the because
they are able to identify several HPV genotypes at the
same time. All studies ISH can be an even more sensitive
method than PCR in cases where only a few cells in the
sample contain high copy numbers of the virus that are
not detectable with PCR (Syrja¨nen, 1990). In the present
meta-analysis, no distinction was made between the
PCR primers used in HPV detection. Inadequate sample
puriﬁcation because of PCR inhibition has been shown
to result in signiﬁcant underestimates of oral HPV
prevalence (Puranen et al, 1997; D’Souza et al, 2007).
Moreover, the quality of the sample (e.g. frozen or ﬁxed)
might signiﬁcantly aﬀect the HPV testing results. Ter-
mine et al showed in their meta-analysis (1988–2007)
that the detection rate of HPV with ISH was higher in
formalin-ﬁxed and paraﬃn-embedded biopsies derived
from OSCC than in other head and neck cancers (38.1%
vs 24.1%). When PCR was used, the detection rate
increased to 39.9% (Termine et al, 2008). Transcrip-
tional activity of HPV oncogenes E6 and E7 is impor-
tant in understanding the role of HPV in oral diseases.
Until now, however, only a few studies on transcrip-
tional activity of HPV in OSCC or OPMD are available
(Koskinen et al, 2003, Badaracco et al, 2007). In all
future studies, the sampling, processing of the samples
as well as PCR protocols should be standardized to
allow for more precise comparison of the results. One
should also recognize the limitations of the selected
HPV testing method with regard to the samples used.
Most of the studies have focused only on HPV16 or a
restricted panel of other HR-HPV genotypes. Further
studies might reveal other genotypes associated with
OPMD and OSCC.
One shortcoming of this meta-analysis is that we
were not able to assess the detailed anatomic location
or histological variants of the oral lesions associated
with HPV because of the lack of the data in original
papers. Importantly, because most of these studies
have failed to collect the data on smoking, drinking
history, sexual habits, age or other potential risk
factors, we made no attempt to analyze the confound-
ing risk factors of HPV. One limitation is also that we
did not categorize the studies by strength of study
design. By the strict selection criteria used here, the
majority of the included studies were considered to
have an inherent risk of bias. Also very few of the
studies that used negative and positive controls stated
Figure 5 Funnel plot of the studies investi-
gating human papillomavirus (HPV) infection
in oral potentially malignant disorder (OP-
MD) and control samples
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the sensitivity of the PCR method used. Another
methodological limitation is the eﬃciency of nucleic
acid isolation which could have been inﬂuenced by
time and temperature of storage.
In conclusion, the results of this meta-analysis
showed a strong association between HPV and OPM-
D ⁄OSCC, thus justifying the rejection of the null
hypothesis that HPV is equally prevalent in normal
Figure 6 Forest plot of human papillomavirus (HPV) prevalence in different subgroup among oral potentially malignant disorder (OPMD) and
control samples
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oral mucosa and OPMD or OSCC. For HPV testing,
biopsy samples are more appropriate than exfoliated
cell samples. In the total lack of prospective cohort
studies, we were unable to take a position on the
temporal relationship between HPV infection and oral
malignancies. To formally conﬁrm the role of HPV as
an etiological agent of OSCC, additional evidence is
required, summarized in the modiﬁed Koch’s postu-
Figure 7 Forest plot of human papillomavirus (HPV) 16 prevalence in different subgroup among oral potentially malignant disorder (OPMD) and
control samples
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lates’ (Haverkos, 2004): (1) viral infection precedes the
development of cancer, which has not yet been formally
shown, although the current case–control approach
gives the best evidence available to date to support this
concept; (2) viral genome present in tumor lesions or in
tumor cells, a ﬁnding that has been conﬁrmed by this
review; (3) epidemiologic association between the pres-
ence of the virus and development of cancer, a fact that
was not shown in the present review because no
randomized case–control studies or follow-up studies
have been published; (4) ability of the virus or viral
proteins to transform cells in vitro, which has been
clearly shown; (5) ability of the virus or viral proteins to
promote tumor formation in animals; an experimental
model exists where HPV16 E6 ⁄E7 expression together
with carcinogen 4NQO induces oral cancer in transgenic
mice within 9 months (Strati et al, 2006, Jabbar et al.
2010); (6) ﬁnally, prophylactic HPV vaccination elimi-
nates OSCC, however, obtaining this ﬁnal proof’ will
require at least 20 years, before the oral cancer preva-
lence in HPV vaccinated and non-vaccinated subjects
can be ascertained epidemiologically.
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